Economic Impact of Therapeutic Choices: The Case of Incretins

Il valore economico della scelta di un percorso terapeutico: il caso delle incretine

Authors

  • Roberto Ravasio Health Publishing & Services, Milano - Italy

DOI:

https://doi.org/10.33393/grhta.2014.317

Keywords:

Self-monitoring, Sitagliptin, Type 2 diabetes

Abstract

The objective of this economic evaluation was to compare two alternative therapeutic regimens for the treatment of type 2 diabetes: basal-bolus insulin vs basal insulin and DPP-4. We conducted a Cost-Minimization Analysis (CMA) to compare the annual cost of basal-bolus insulin regimen vs basal insulin and DPP-4 regimen from the perspective of the Italian National Health Service (NHS). The CMA considered only direct medical costs (basal insulin, bolus insulin and DPP-4 [sitagliptin] and self-monitoring of glycemic control). Costs were assessed in 2014 Euros. Sensitivity analysis and threshold analysis on key economic parameters were performed. The expected annual cost (per patient) was €987.60 with basal insulin and DPP-4 and €1,568.23 with basal-bolus insulin. As a consequence of a significant reduction of glycemic control costs, the regimen with DPP-4 was a cost-saving alternative from the perspective of the Italian NHS.

Downloads

Published

2021-07-23

How to Cite

1.
Ravasio R. Economic Impact of Therapeutic Choices: The Case of Incretins: Il valore economico della scelta di un percorso terapeutico: il caso delle incretine. Grhta [Internet]. 2021 Jul. 23 [cited 2022 Oct. 1];1(2):52-8. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/317

Issue

Section

Point of View

Most read articles by the same author(s)

1 2 3 4 > >>